2022 Year in Review: Securities Litigation Against Life Sciences Companies

We are proud to present our seventh annual Securities Litigation Year in Review publication, in which we analyze data for securities class actions filed nationally against publicly traded pharmaceutical, biotechnology, medical device, and healthcare product and services companies (collectively referred to herein as “life sciences companies”) and summarize important decisions issued by courts in 2022 in key jurisdictions in these cases. These cases are typically filed by shareholders, on behalf of a putative class, seeking to recover investment losses after a company's stock price drops following the disclosure of a setback or problem experienced by the company with respect to its drugs or products, such as negative feedback from or action by the FDA, clinical trial delays, suspensions or terminations, negative clinical data results, adverse events experienced by patients, or manufacturing problems. Plaintiffs typically assert claims under Sections 10(b) and 20(a) and Rule 10b-5 of the Securities Exchange Act of 1934 (the 1934 Act) based upon allegedly false and misleading statements or omissions made by the company and its officers, and/or, if the alleged misstatements or omissions are made in connection with a registered securities offering, under Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 (the 1933 Act). Please see full Publication below for more information.
Source: 2022 Year in Review: Securities Litigation Against Life Sciences Companies